Bristol-Myers Squibb (BMY)

Date: December 15, 2025 1. Introduction Bristol Myers Squibb (BMS) (NYSE: BMY) is a global biopharmaceutical powerhouse focused on discovering, developing, manufacturing, and distributing innovative medicines for serious diseases. As of December 15, 2025, BMS stands at a critical juncture, balancing the impending "patent cliff" for several of its blockbuster drugs with a strategically diversified [...]

Shares of biopharmaceutical company Bristol Myers Squibb (NYSE:BMY) jumped 3.7% in the afternoon session after BofA Securities upgraded the company's stock from "Neutral" to "Buy" and increased its price target. 

Stay informed about the performance of the S&P500 index in the middle of the day on Monday. Uncover the top gainers and losers in today's session for valuable insights.

The US market session of Monday has yet to be opened, let's have a look at the top S&P500 gainers and losers in the pre-market session today.

These dividend growth machines could have considerable upside for long-term investors.

Here are three stocks offering attractive yields of up to 4.9%, each backed by strong businesses.

Stay informed about the performance of the S&P500 index one hour before the close of the markets on Friday. Uncover the top gainers and losers in today's session for valuable insights.

Shares of biopharmaceutical company Bristol Myers Squibb (NYSE:BMY) jumped 2.6% in the afternoon session after an analyst at Guggenheim upgraded the company's stock from "Neutral" to "Buy" and set a new price target of $62. 

Join us in exploring the top gainers and losers within the S&P500 index in the middle of the day on Friday as we examine the latest happenings in today's session.

Pfizer and Bristol Myers Squibb are deeply out-of-favor drugmakers, but one could be the better turnaround candidate if you think long term.

Wall Street has issued downbeat forecasts for the stocks in this article. These predictions are rare - financial institutions typically hesitate to say bad things about a company because it can jeopardize their other revenue-generating business lines like M&A advisory.

As of December 12, 2025, the financial markets are witnessing a significant "Great Rotation," a pronounced shift of capital from high-growth technology and Artificial Intelligence (AI) stocks to more traditional value sectors and defensive equities. This ongoing recalibration reflects evolving macroeconomic conditions, a reassessment of risk appetite, and a growing

Investors are currently so focused on one type of drug that even good companies are being left on the sidelines.

Large-cap stocks have the power to shape entire industries thanks to their size and widespread influence. With such vast footprints, however, finding new areas for growth is much harder than for smaller, more agile players.

These three drugmakers are all well off their recent highs. Is this a sign of opportunity or risk?

Stocks in the $10-50 range offer a sweet spot between affordability and stability as they’re typically more established than penny stocks. But their headline prices don’t guarantee quality, and investors should exercise caution as some have shaky business models.

Wondering what's happening in today's session for the S&P500 index? Stay informed with the top movers within the S&P500 index on Wednesday.

Stay updated with the movements of the S&P500 index in the middle of the day on Wednesday. Discover which stocks are leading as top gainers and losers in today's session.

Bristol Myers’ ADEPT-2 update drew support from JPMorgan and William Blair following the decision to continue the study with added enrollment.

Let's have a look at what is happening on the US markets before the opening bell on Wednesday. Below you can find the top S&P500 gainers and losers in today's pre-market session.

Amazon (NASDAQ: AMZN) has unveiled a groundbreaking class of AI agents, dubbed "frontier agents," capable of operating autonomously for extended periods—even days—without constant human intervention. Announced at the Amazon Web Services (AWS) re:Invent conference on December 2, 2025, this development marks a pivotal moment in the evolution of artificial intelligence, signaling a significant shift from [...]

Bristol-Myers Squibb (BMY) presents a value investment case, trading at a deep discount with strong earnings power and a high dividend amid near-term challenges.

If you are looking to own a stock for the long term, these out-of-favor drugmakers have proven they have what it takes to survive.

Patience will be rewarded for those who stick with these two healthcare stocks.

The pharma stock yields more than 4x the S&P 500 average.